Overview

A Study of LY2922083 in Healthy Participants and Participants With Diabetes

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study consists of two parts. Part A will study healthy participants in up to 3 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 6 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company